Fusion with antibodies targeting fibroblast activation protein (FAP) and carcinoembryonic antigen (CEA) can enhance their tumor-targeting capabilities and mitigate cytotoxicity caused by IL-2 retention in peripheral blood (108, 109). The gene discussed is CEACAM5; the disease is neoplasm.